Clinical evaluation of the risk-benefit profile of biological therapies in the management of psoriatic arthritis

Clinical evaluation of the risk-benefit profile of biological therapies in the management of psoriatic arthritis

Psoriatic arthritis (PsA) Is a chronic autoimmune inflammatory condition that has skin and joint components. Understanding the pathophysiology of the disease has paved the way for a breakthrough in its management with the introduction of antitumour necrosis factor therapies (TNFs). However, little i...

Full description

Bibliographic Details
Main Author: Saad, Amr Abdel Moneim Abdel Rahman
Published: University of Manchester 2009
Subjects:
616.72206
Online Access:http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.506253
id ndltd-bl.uk-oai-ethos.bl.uk-506253
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-5062532015-03-20T05:14:50ZClinical evaluation of the risk-benefit profile of biological therapies in the management of psoriatic arthritisSaad, Amr Abdel Moneim Abdel Rahman2009Psoriatic arthritis (PsA) Is a chronic autoimmune inflammatory condition that has skin and joint components. Understanding the pathophysiology of the disease has paved the way for a breakthrough in its management with the introduction of antitumour necrosis factor therapies (TNFs). However, little is known about their long-term risk-benefit profile, as well as, long-term persistence with these therapies in patients with PSA. The aim of this thesis was to conduct a meta-analysis of published randomised controlled trials followed by a longitudinal observational study of the use of anti-TNF therapies in PSA.616.72206University of Manchesterhttp://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.506253Electronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 616.72206
spellingShingle 616.72206
Saad, Amr Abdel Moneim Abdel Rahman
Clinical evaluation of the risk-benefit profile of biological therapies in the management of psoriatic arthritis
description Psoriatic arthritis (PsA) Is a chronic autoimmune inflammatory condition that has skin and joint components. Understanding the pathophysiology of the disease has paved the way for a breakthrough in its management with the introduction of antitumour necrosis factor therapies (TNFs). However, little is known about their long-term risk-benefit profile, as well as, long-term persistence with these therapies in patients with PSA. The aim of this thesis was to conduct a meta-analysis of published randomised controlled trials followed by a longitudinal observational study of the use of anti-TNF therapies in PSA.
author Saad, Amr Abdel Moneim Abdel Rahman
author_facet Saad, Amr Abdel Moneim Abdel Rahman
author_sort Saad, Amr Abdel Moneim Abdel Rahman
title Clinical evaluation of the risk-benefit profile of biological therapies in the management of psoriatic arthritis
title_short Clinical evaluation of the risk-benefit profile of biological therapies in the management of psoriatic arthritis
title_full Clinical evaluation of the risk-benefit profile of biological therapies in the management of psoriatic arthritis
title_fullStr Clinical evaluation of the risk-benefit profile of biological therapies in the management of psoriatic arthritis
title_full_unstemmed Clinical evaluation of the risk-benefit profile of biological therapies in the management of psoriatic arthritis
title_sort clinical evaluation of the risk-benefit profile of biological therapies in the management of psoriatic arthritis
publisher University of Manchester
publishDate 2009
url http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.506253
work_keys_str_mv AT saadamrabdelmoneimabdelrahman clinicalevaluationoftheriskbenefitprofileofbiologicaltherapiesinthemanagementofpsoriaticarthritis
_version_ 1716789761886126080

Similar Items